Skip to content
An Initiative of AVAC
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By
Multiple filters can be used at once

Showing results 121 - 130 of 144

Selected Filters:
7 January 2020

Market Authorization 101

This slide deck outlines a potential path of market authorization for the dapivirine vaginal ring. It clarifies the necessary regulatory, normative guidance, and policy steps at the global and country levels that would be needed to support ring introduction. This Market Authorization 101 deck is intended to illustrate the ring pathway to market and assist…

Normative Guidance/Policies

Document
10 October 2019

The Dapivirine Ring: Key learnings from like-product introductions

Vaginal insertion and partial efficacy are two challenges that could affect the uptake and continued use of the dapivirine ring. Analyses of the introductions of other products that share similar characteristics provide useful lessons to inform planning for rollout of the dapivirine ring. This paper provides information for planners, implementers, funders, researchers, trainers, providers of…

Research

Document
10 October 2019

Social Harms and Use of the Dapivirine Vaginal Ring

The dapivirine ring and other woman-initiated HIV prevention methods are designed to enable women to have more control over their sexual health and risk of HIV exposure, but research has revealed that women's male partners often influence their ability to use these methods. This brief summarizes an analysis of MTN-020/ASPIRE trial data, which showed that…

Research

Document
8 April 2019

Dapivirine Ring Early Introduction Considerations — Tanzania Analysis

The OPTIONS Consortium conducted secondary research and interviews with key stakeholders in several countries to understand questions about the ring that could inform demonstration and processes for introducing new biomedical HIV prevention products. Tanzania was prioritized for analysis due to the state of the HIV epidemic in the country and experience with ring trials. (For…

Research

Document
8 April 2019

Dapivirine Ring Early Introduction Considerations — Malawi Analysis

The OPTIONS Consortium conducted secondary research and interviews with key stakeholders in several countries to understand questions about the ring that could inform demonstration and processes for introducing new biomedical HIV prevention products. Malawi was prioritized for analysis due to the state of the HIV epidemic in the country and experience with ring trials. (For…

Research

Document
8 April 2019

Dapivirine Ring Early Introduction Considerations — Zimbabwe Analysis

The OPTIONS Consortium conducted secondary research and interviews with key stakeholders in several countries to understand questions about the ring that could inform demonstration and processes for introducing new biomedical HIV prevention products. Zimbabwe was prioritized for analysis due to the state of the HIV epidemic in the country and experience with ring trials. (For…

Research

Document
8 April 2019

Dapivirine Ring Early Introduction Considerations — Kenya Analysis

The OPTIONS Consortium conducted secondary research and interviews with key stakeholders in several countries to understand questions about the ring that could inform demonstration and processes for introducing new biomedical HIV prevention products. Kenya was prioritized for analysis due to the state of the HIV epidemic in the country and experience with ring trials. (For…

Research

Document
8 April 2019

Dapivirine Ring Early Introduction Considerations — Uganda Analysis

The OPTIONS Consortium conducted secondary research and interviews with key stakeholders in several countries to understand questions about the ring that could inform demonstration and processes for introducing new biomedical HIV prevention products. Uganda was prioritized for analysis due to the state of the HIV epidemic in the country and experience with ring trials. (For…

Research

Document
8 April 2019

Dapivirine Ring Early Introduction Considerations — Rwanda Analysis

The OPTIONS Consortium conducted secondary research and interviews with key stakeholders in several countries to understand questions about the ring that could inform demonstration and processes for introducing new biomedical HIV prevention products. Rwanda was prioritized for analysis due to the state of the HIV epidemic in the country and experience with ring trials. (For…

Research

Document
8 April 2019

Dapivirine Ring Early Introduction Considerations — Seven Country Analysis

The OPTIONS Consortium conducted secondary research and interviews with key stakeholders in several countries to understand questions about the ring that could inform demonstration and processes for introducing new biomedical HIV prevention products. Rwanda, Uganda, Kenya, Zimbabwe, Malawi, Tanzania and South Africa were prioritized for analysis due to the state of the HIV epidemic in…

Research

Document